Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
UK airport passengers have to walk up to a kilometer from check-in desks to reach their departure gates, new research has shown.
In an annual survey taken among local authorities in the UK, 2,463 stray dogs were put to sleep between April 2015 and March 2016.
Inspectors found the availability of drugs at HMP Bedford was having a "serious impact" on safety.